SCHEMBL17829692

SCHEMBL17829692

O=Cc1c[nH]c2c(Cl)c(Cl)ccc12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.50
CSNK2B P67870 2/20 0.50
CSNK2A1 P68400 2/20 0.50
TRIM24 O15164 1/20 0.50
TRIM33 Q9UPN9 1/20 0.50
PIM3 Q86V86 10/20 0.49
PIM1 P11309 8/20 0.49
PIM2 Q9P1W9 2/20 0.49
CYP2A6 P11509 2/20 0.43
IMPDH2 P12268 1/20 0.43
IDO1 P14902 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31656115 0.82 TRIM24 (0.56) CSNK2A2CSNK2BCSNK2A1TRIM24TRIM33
SCHEMBL29952798 0.82 PIM3 (0.50) CSNK2A2CSNK2BCSNK2A1TRIM24TRIM33
SCHEMBL30859480 0.82 PIM3 (0.51) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL2534041 0.82 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29950839 0.82 TRIM24 (0.47) CSNK2A2CSNK2BCSNK2A1TRIM24TRIM33
SCHEMBL17828249 0.82 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29951655 0.82 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL29958526 0.82 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL14519078 0.82 PIM3 (0.65) TRIM24TRIM33PIM3PIM1PIM2
SCHEMBL30968925 0.78 TRIM24 (0.47) TRIM24TRIM33PIM3PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
WO-2016094730-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS, INC. (US) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS FOS, FOSB, YAP1 CSNK2A2 3044/4885CSNK2B 2971/4885CSNK2A1 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.